PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Lycorine reduced sarcoma growth in S180 tumour-bearing mice and inhibited MCF-7 cell proliferation in a concentration-dependent manner [PMID:39175104]
Lycoris radiata extracts showed anti-SARS-CoV effects with a median effective concentration of 2.4-88.2 μg/mL [PMID:33155905]; other reviews note promising inhibitory effects against coronavirus [PMID:33037698]
Lycorine demonstrated antiviral efficacy and immunomodulatory mechanisms in DF-1 cells and SPF chicken models [PMID:41933747]
Certain alkaloids from the bulbs showed significant neuroprotective effects against H2O2, CoCl2, and Aβ(25-35)-induced SH-SY5Y cell injury [PMID:23669033]
Hippeastrine strongly inhibited the proliferation of HT-29 and Hep G2 cells [PMID:27922057]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 26985918 (2016) — Karyotype studies on Lycoris radiata populations from China. · Genetics and molecular research : GMR
- 2.PMID: 41473140 (2025) — Medicinal compounds and biotechnology of Amaryllidaceae alkaloids in Lycoris radiata. · Frontiers in plant science
- 3.PMID: 38105545 (2024) — Interplay between Amaryllidaceae alkaloids, the bacteriome and phytopathogens in Lycoris radiata. · The New phytologist
- 4.PMID: 16172532 (2005) — Genetic variations in Lycoris radiata var. radiata in Japan. · Genes & genetic systems
- 5.PMID: 39175104 (2024) — Lycorine (Lycoris radiata)-a unique natural medicine on breast cancer.